ACT Advisors’s Heron Therapeutics HRTX Stock Holding History

ACT Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22.8K	Buy	28,443 +2,635	+10%	+$3.05K	0.01%	73
2025 Q4	$33.5K	Buy	25,808 +227	+0.9%	+$280	0.01%	61
2025 Q3	$32.2K	Sell	25,581 -74	-0.3%	-$117	0.01%	67
2025 Q2	$53.1K	Buy	25,655 +74	+0.3%	+$151	0.02%	56
2025 Q1	$56.3K	Hold	25,581	–	–	0.03%	53
2024 Q4	$39.1K	Hold	25,581	–	–	0.02%	49
2024 Q3	$50.9K	Buy	25,581 +3,436	+16%	+$8.2K	0.02%	50
2024 Q2	$77.5K	Hold	22,145	–	–	0.04%	44
2024 Q1	$61.3K	Hold	22,145	–	–	0.03%	43
2023 Q4	$37.6K	Buy	+22,145	New	+$24.4K	0.02%	42

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

ACT Advisors's HRTX Position: Q1 2026 in Review

ACT Advisors increased its Heron Therapeutics (HRTX) stake by 10% in Q1 2026, buying an estimated $3.05K and bringing the position to 28,443 shares worth $22.8K. The position accounts for 0.01% of the portfolio, ranked #73.

ACT Advisors first reported a position in HRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $77.5K in Q2 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

ACT Advisors held 28,443 shares of Heron Therapeutics worth $22.8K as of Q1 2026.
ACT Advisors bought 2,635 Heron Therapeutics shares in Q1 2026, an estimated $3.05K.
Heron Therapeutics made up 0.01% of ACT Advisors's portfolio in Q1 2026, its #73 holding.
ACT Advisors first reported a position in Heron Therapeutics in Q4 2023 and has held it in 10 quarters since.
ACT Advisors's Heron Therapeutics position peaked at $77.5K in Q2 2024.
167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on ACT Advisors's 13F filing for Q1 2026, filed 14 Apr 2026.